Table 1 Theranostic agents approved for PCa in the 21st century
From: Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
International non-proprietary name (INN) | Brand name | Pharmacotherapeutic group | EMA approval date | FDA approval date | China NMPA approval date |
|---|---|---|---|---|---|
Zoledronic acid | Zometa | Bone-targeting therapy | Mar 2001 | Feb 2002 | Dec 2018 |
Degarelix | Firmagon | Endocrine therapy | Feb 2009 | Dec 2008 | July 2019 |
Sipuleucel-T | Provenge | Immunotherapy | Sept 2013 | Apr 2010 | / |
Cabazitaxel | Jevtana | Antineoplastic agents | Mar 2011 | Jun 2010 | / |
Denosumab | Prolia/Xgeva | Bone-targeting therapy | July 2011 | Nov 2010 | May 2019 |
Abiraterone | Zytiga | Endocrine therapy | Sept 2011 | Apr 2011 | Dec 2019 |
Enzalutamide | Xtandi | Endocrine therapy | Jun 2013 | Aug 2012 | Nov 2019 |
Radium-223 dichloride | Xofigo | Therapeutic radiopharmaceuticals | Nov 2013 | May 2013 | Aug 2020 |
Fluciclovine (18F) | Axumin | Diagnostic radiopharmaceuticals | May 2017 | May 2016 | / |
Pembrolizumab | Keytruda | Immunotherapy | / | May 2017 | / |
Padeliporfin | Tookad | Antineoplastic agents | Sept 2017 | / | / |
Darolutamide | Nubeqa | Endocrine therapy | Mar 2020 | Jul 2019 | Feb 2021 |
Rucaparib | Rubraca | Antineoplastic agents | / | May 2020 | / |
Olaparib | Lynparza | Antineoplastic agents | Nov 2020 | May 2020 | Jun 2021 |
Relugolix | Orgovyx | Endocrine therapy | Mar 2022 | Dec 2020 | / |
Piflufolastat F 18 | Pylarify | Diagnostic radiopharmaceuticals | / | May 2021 | / |
Dostarlimab-gxly | Jemperli | Immunotherapy | / | Aug 2021 | / |
177Lu-PSMA-617 | Pluvicto | Therapeutic radiopharmaceuticals | / | Mar 2022 | / |
68Ga-PSMA-11 | Locametz | Diagnostic radiopharmaceuticals | / | Mar 2022 | / |
